Comparison of Cardiovascular Events in Patients With Angiographically Documented Coronary Narrowing With Combined Renin-Angiotensin System Inhibitor Plus Statin Versus Renin-Angiotensin System Inhibitor Alone Versus Statin Alone (from the Japanese Coronary Artery Disease Study)

American Journal of Cardiology

Volumn 100, Issue 12, 2007, Pages 1750-1753

  Fujita, Masatoshi ^a   Yamazaki, Tsutomu ^b   Hayashi, Dobun ^b   Kohro, Takahide ^b   Okada, Yoshihiro ^b   Nagai, Ryozo ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 36849020157     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.07.025     Document Type: Article

References (9)

1. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
2. Wassmann S., Stumpf M., Strehlow K., Schmid A., Schieffer B., Bohm M., and Nickenig G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94 (2004) 534-541
3. Nickenig G. Should angiotensin II receptor blockers and statins be combined?. Circulation 110 (2004) 1013-1020
4. The Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan: the Japanese Coronary Artery Disease Study (The JCAD Study). Circ J 70 (2006) 1256-1262
5. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
6. Yamamoto E., Yamashita T., Tanaka T., Kataoka K., Tokutomi Y., Lai Z.F., Dong Y.F., Matsuba S., Ogawa H., and Kim-Mitsuyama S. Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol 27 (2007) 556-563
7. Esper R.J., Machado R., Vilariño J., Cacharrün J.L., Ingino C.A., Guiñazú C.A.G., Bereziuk E., Bolaño A.L., and Suarez D.H. Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined. Am Heart J 140 (2000) 684-689
8. Koh K.K., Son J.W., Ahn J.Y., Kim D.S., Jin D.K., Kim H.S., Han S.H., Seo Y.H., Chung W.J., Kang W.C., and Shin E.K. Simvastain combined with ramipril treatment in hypercholesterolemic patients. Hypertension 44 (2004) 180-185
9. Teo K.K., Burton J.R., Buller C.E., Plante S., Catellier D., Tymchak W., Dzavik V., Talor D., Yokoyama S., and Montague T.J. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 102 (2000) 1748-1754